Cancer Gene Therapy Market Report 2025

The cancer gene therapy market size has grown rapidly in recent years. It will grow from $3.61 billion in 2024 to $4.21 billion in 2025 at a compound annual growth rate (CAGR) of 16.6%. The growth in the historic period can be attributed to increasing awareness of oncovirus-related cancers, rising collaborations between biotechnology companies and academic institutions, expanding clinical trial activity in early-phase gene therapies, growing demand for ex vivo modified cell therapies, and a surge in strategic licensing agreements for gene therapy platforms.

The cancer gene therapy market size is expected to see rapid growth in the next few years. It will grow to $7.67 billion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to increasing focus on non-viral delivery systems, expanding availability of companion diagnostics, rising interest in off-the-shelf allogeneic cell therapies, growth of contract development and manufacturing organizations (CDMOs), and advances in synthetic biology enabling customizable gene circuits. Major trends in the forecast period include advancements in non-viral gene delivery platforms, automation in gene therapy manufacturing, development of synthetic promoters for cancer-specific expression, innovations in intratumoral gene therapy administration, and emergence of multiplexed gene modulation strategies.

The rising cancer incidence is expected to propel the growth of the cancer gene therapy market going forward. Cancer refers to the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body. The increasing number of cancer cases is driven by rising life expectancy, as the risk of developing cancer increases with age. Cancer gene therapy addresses this by modifying or replacing faulty genes to inhibit cancer cell growth or enhance the immune system’s ability to target cancer cells. For instance, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that over 3 million people in the UK were living with cancer, projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising cancer incidence is driving the growth of the cancer gene therapy market.

Prominent companies in the cancer gene therapy market are developing advanced treatments, such as CAR-T cell therapy, to improve precision, enhance patient outcomes, and selectively target cancer cells while sparing healthy tissues. CAR-T therapy is an immunotherapy where a patient’s T cells are engineered with special receptors to recognize and destroy cancer cells. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, launched NexCAR19 (actalycabtagene autoleucel), India’s first indigenously developed CAR-T therapy for B-cell lymphomas and leukemias. The therapy reprograms the patient’s T cells to attack cancer cells and is locally manufactured, making it more affordable and accessible than imported alternatives.

In May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, acquired EsoBiotec B.V., a Switzerland-based biotechnology firm specializing in cancer gene therapies. This acquisition aims to strengthen AstraZeneca’s cell therapy pipeline and accelerate the development of next-generation oncology and immune-mediated disease treatments.

Major players in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc.

North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cancer gene therapy is a treatment approach that employs specific genes to combat cancer by modifying or introducing genes in a patient’s cells to inhibit cancer growth. This strategy enables the body to target cancer more effectively, offering a more precise and less harmful alternative to conventional treatments.

The primary types of cancer gene therapies include gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. Gene-induced immunotherapy enhances the immune system through genetic modification, improving its ability to detect and destroy cancer cells. It is applied in indications such as large B-cell lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), and melanoma. These therapies use various vector types, including lentivirus, retrovirus and gamma retrovirus, adeno-associated virus (AAV), modified herpes simplex virus, and adenovirus. End users include hospitals, research institutes, biopharmaceutical companies, diagnostic centers, and others.

The cancer gene therapy market research report is one of a series of new reports that provides cancer gene therapy market statistics, including cancer gene therapy industry global market size, regional shares, competitors with a cancer gene therapy market share, detailed cancer gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer gene therapy industry. This cancer gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer gene therapy market consists of revenues earned by entities by providing services such as gene delivery services, clinical trial services, gene editing, and cell-based therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer gene therapy market also includes sales of gene therapy drugs, viral vectors, non-viral delivery systems, and plasmids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.